Fixed Low-Dose Antihypertensive Therapy

Comprehensive Hypertension

Volumn , Issue , 2007, Pages 1061-1073

  Woodham, Ryan M ^a   Oparil, Suzanne ^b,c  

^a University of Alabama at Birmingham   (United States)

^b Center for Aging   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649326622     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03961-1.50089-1     Document Type: Chapter

References (80)

1. LE Fields, VL Burt, JA Cutler, et al. (2004) The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension 44 398-404.
2. F Turnbull, B Neal, C Algert, et al. (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomized trials: Blood Pressure Lowering Treatment Trialists Collaboration. Lancet 362 1527-1535.
3. S Lewington, R Clarke, N Qizilbash, et al. (2002) Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 360 1903-1913.
4. DM Lloyd-Jones, JC Evans and D Levy (2005) Hypertension in adults across the age spectrum: Current outcomes and control in the community. JAMA 294 466-472.
5. SS Franklin, W Gustin, ND Wong, et al. (1997) Hemodynamic patterns of age-related changes in blood pressure: The Framingham heart study. Circulation 96 308-315.
6. V Franco, S Oparil and OA Carretero (2004) Hypertensive therapy: Part II. Circulation 109 3081-3088.
7. R Collins, R Peto, S MacMahon, et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 335 827-839.
8. B Neal, S MacMahon, N Chapman, et al. (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressures Lowering Treatment Trialists' Collaboration. Lancet 356 1955-1964.
9. JA Staessen, JG Wang and L Thijs (2001) Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 358 1305-1315.
10. JA Staessen, Y Li, L Thijs and JG Wang (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 28 385-407.
11. AV Chobanian, GL Bakris, HR Black, et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 289 2560-2572.
12. AV Chobanian, GL Bakris, HR Black, et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 1206-1252.
13. WC Cushman, CE Ford, JA Cutler, et al. (2002) Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 4 393-404.
14. DA Sica (2002) Rationale for fixed-dose combination in the treatment of hypertension: The cycle repeats. Drugs 62 443-462.
15. Veterans Administration Cooperative Study on Anti-hypertensive Agents (1967) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 202 1028-1034.
16. L Osterberg and P Rudd (2005) Medication adherence for antihypertensive therapy. S Oparil, MA Weber (Eds) Hypertension: A Companion to Brenner and Rector's the Kidney Second Edition Philadelphia, PA: Elsevier Saunders 430-446.
17. JM Neutel, DH Smith and MA Weber (2001) Low-dose combination therapy: An important first-line treatment in the management of hypertension. Am J Hypertens 14 286-292.
18. S Oparil, MA Zaman and DA Calhoun (2003) Pathogenesis of hypertension. Ann Intern Med 139 761-776.
19. AC Guyton (1991) Blood pressure control-special role of the kidneys and body fluids. Science 252 1813-1816.
20. RD Brook and S Julius (2000) Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens 13 112S-122S.
21. MA Zaman, S Oparil and DA Calhoun (2002) Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 1 621-636.
22. S Oparil and E Haber (1974) The renin-angiotensin system. N Engl J Med 291 389-401. 446–57
23. HR Brunner, JH Laragh, L Baer, et al. (1972) Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286 441-449.
24. MH Alderman, S Madhavan, WL Ooi, et al. (1991) Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324 1098-1104.
25. MA Knepper, T Kleyman and G Gamba (2005) Diuretics: Mechanisms of action. S Oparil, MA Weber (Eds) Hypertension: A Companion to Brenner and Rector's the Kidney, Second Edition Philadelphia, PA: Elsevier Saunders 638-652.
26. CS Wilcox (1999) Metabolic and adverse effects of diuretics. Semin Nephrol 19 557-568.
27. LE Ramsay, WW Yeo and PR Jackson (1992) Diabetes, impaired glucose tolerance and insulin resistance with diuretics. Euro Heart J 13(Suppl G), 68-71.
28. E Saunders, MR Weir, BW Kong, et al. (1990) A comparison of the efficacy and safety of a beta blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 150 1707-1713.
29. AH Gradman, RE Schmieder, RL Lins, et al. (2005) Aliskiren: A novel orally effective renin inhibitor, provides dose-dependant antihypertensive efficacy and placebolike tolerability in hypertensive patients. Circulation 111 1012-1018.
30. NJ Brown and DE Vaughan (1998) Angiotensin-converting enzyme inhibitors. Circulation 97 1411-1420.
31. CP Tiefenbacher, S Friedrich, T Bleeke, et al. (2004) ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol 286 1425-1432.
32. RM Carey and HM Siragy (2003) Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev 24 261-271.
33. EM Lonn, S Yusuf, V Dzavik, et al. (2001) Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 103 919-925.
34. S Yusuf, P Sleight, J Pogue, et al. (2000) Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: The Heart Outcomes Prevention Evaluation (HOPE) study investigators. N Engl J Med 342 145-153.
35. T Elung-Jensen, J Heisterberg, AL Kamper, et al. (2003) Blood pressure response to conventional and low-dose enalapril in chronic renal failure. Br J Clin Pharmacol 55 139-146.
36. ZH Israili and WD Hall (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 117 234-242.
37. NJ Brown, WA Ray, M Snowden and MR Griffin (1996) Black Americans have increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60 8-13.
38. JB Kostis, M Packer, HR Black, et al. (2004) Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment Vs. Enalapril (OCTAVE) trial. Am J Hypertens 17 103-111.
39. DE Hricik, PJ Browning, R Kopelman, et al. (1983) Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 308 373-376.
40. VJ Dzau (1987) Renal effects of angiotensin-converting enzyme inhibitor in cardiac failure. Am J Kidney Dis 10(Suppl 1), 74-80.
41. BF Murphy, JA Whitworth and P Kincaid-Smith (1984) Renal insufficiency with combination of angiotensin converting enzyme inhibitors and diuretics. Br Med J (Clin Res Ed) 288 844-845.
42. MA McDonald, SH Simpson, JA Ezekowitz, et al. (2005) Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 331 873-877.
43. Blood Pressure Lowering Treatment Trialists' Collaboration. The comparative effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on stroke, myocardial infarction and heart failure; (in press).
44. K Teo, S Yusuf, P Sleight, et al. (2004) Rationale, design and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and the combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trial. Am Heart J 148 52-61.
45. R Abdi, VM Dong, CJ Lee and KA Ntoso (2002) Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 22 1173-1175.
46. M Burnier (2001) Angiotensin II type 1 receptor blockers. Circulation 103 904-912.
47. EG McMahon (2003) Eplerenone, a new selective aldosterone blocker. Curr Pharm Des 9 1065-1075.
48. RS Mckelvie, S Yusuf, D Pericak, et al. (1999) Comparison of candesartan, enalapril and their combinationin congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 100 1056-1064.
49. DR Abernethy and JB Schwartz (1999) Calcium-antagonist drugs. N Engl J Med 341 1447-1457.
50. WH Frishman (2005) Beta adrenergic blockers. S Oparil, MA Weber (Eds) Hypertension: A Companion to Brenner and Rector's the Kidney Second Edition Philadelphia, PA: Elsevier Saunders 653-659.
51. B Carlberg, O Samuelesson and LH Lindholm (2004) Atenolol in hypertension: Is it a wise choice? Lancet 364 1684-1689.
52. LH Lindholm, B Carlberg and O Samuelsson (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 1545-1553.
53. MR Weir and VJ Dzau (2001) The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens 12(Suppl 1), 177S-181S.
54. EJ Lewis, LG Hunsicker, RP Bain and RD Rohde (1993) For the collaborative study group: The effect of angiotensin-converting-enzyme inhibitor on diabetic nephropathy. N Engl J Med 329 1456-1462.
55. DR Singer, ND Markandu, AL Sugden, et al. (1991) Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension 17 798-803.
56. L Welsh and A Ferro (2004) Drug treatment of essential hypertension: The case for initial combination therapy. Int J Clinic Pract 58 956-963.
57. Veterans Administration Co-operative Study Group on Antihypertensive Agents (1982) Racial differences in response to low dose captopril are abolished by addition of hydrochlorothiazide. Br J Clin Pharmacol 14(Suppl 2), 97S-101S.
58. DA Sica and E Ripley (2000) Low-dose fixed-combination antihypertensive therapy. S Oparil, MA Weber (Eds) Hypertension: A Companion to Brenner and Rector's the Kidney, Second Edition Philadelphia, PA: WB. Saunders 497-504.
59. SG Chrysant (1994) Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Arch Intern Med 154 737-743.
60. SG Chrysant, MA Weber, AC Wang and DJ Hinman (2004) Evaluation of antihypertensive therapy with combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 17 252-259.
61. D Canter, GJ Frank, LE Knapp, et al. (1994) Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens 8 155-162.
62. P Verdecchia, G Reboldi, F Angeli, et al. (2004) Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 963-969.
63. JB Kostis, AC Wilson, RS Freudenberger, et al. (2005) Long-term effect of diuretic based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 29-35.
64. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 2981-2997.
65. H Abuissa, PG Jones, SP Marso and JH O'Keefe (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta analysis of randomized clinical trials. J Am Coll Cardiol 46 821-826.
66. EL Gillespie, CM White, M Kardas, et al. (2005) The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on development of new-onset type 2 diabetes. Diabetes Care 28 2261-2266.
67. DS Siscovick, TE Raghunathan, BM Psaty, et al. (1994) Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330 1852-1857.
68. ME Davidov, FE Becker and JW Hollifield (1987) Serum magnesium and potassium levels in hypertensive patients after a therapeutic switch from hydrochlorothiazide plus a potassium supplement to maxzide. Am J Med 82(Suppl 3A), 48-51.
69. T Dyckner and PO Wester (1987) Potassium/magnesium depletion in patients with cardiovascular disease. Am J Med 82(Suppl 3A), 11-17.
70. B Dahlof, PS Sever, NR Poulter, et al. (2005) Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicenter randomized controlled trial. Lancet 366 895-906.
71. NR Poulter, H Wedel, B Daholf, et al. (2005) Role of blood pressure and other variables in the differential cardiovascular events rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366 907-913.
72. R Pedrinelli, G Dell'Omo, E Melillo and M Mariani (2000) Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension 35 621-625.
73. FH Messerli, MR Weir and JM Neutel (2002) Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 15 550-556.
74. KA Jamerson, O Nwose, L Jean-Louis, et al. (2004) Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 17 495-501.
75. AH Gradman, NR Cutler, PJ Davis, et al. (1997) Combined enalapril and felodipine extended release for systemic hypertension. Am J Cardiol 79 431-435.
76. Veterans Administration Cooperative Study Group on Hypertensive Agents. (1983) Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol 52 1230-1237.
77. B Dahlof, RB Devereux, SE Kjeldsen, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 359 995-1003.
78. NJ Wald and MR Law (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 1419-1422.
79. MR Law, NJ Wald, JK Morris and RE Jordan (2003) Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326 1427-1435.
80. R Blank, J LaSalle, R Reeves, et al. (2005) Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 7 264-273.